In April 2009 I told you about a pilot study in which low-dose naltrexone (LDN) showed great promise as a fibromyalgia treatment. In that study, all 10 of the participants reported a reduction in fibromyalgia symptoms, with 60% of them experiencing more than a 30% reduction in pain and fatigue.
More recently, Jarred Younger, PhD, of Stanford University School of Medicine, and colleagues (authors of the first study) presented their findings from a second LDN study at the American Academy of...
